344 related articles for article (PubMed ID: 35330159)
1. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.
Zhang X; Li H; Lv X; Hu L; Li W; Zi M; He Y
Life (Basel); 2022 Mar; 12(3):. PubMed ID: 35330159
[TBL] [Abstract][Full Text] [Related]
2. Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.
Zhang C; Wang L; Xu C; Xu H; Wu Y
Front Pharmacol; 2023; 14():1079924. PubMed ID: 36959853
[TBL] [Abstract][Full Text] [Related]
3. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
[TBL] [Abstract][Full Text] [Related]
4. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
Bai X; Yi M; Jiao Y; Chu Q; Wu K
Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
Vafaei S; Zekiy AO; Khanamir RA; Zaman BA; Ghayourvahdat A; Azimizonuzi H; Zamani M
Cancer Cell Int; 2022 Jan; 22(1):2. PubMed ID: 34980128
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Yi M; Yu S; Qin S; Liu Q; Xu H; Zhao W; Chu Q; Wu K
J Hematol Oncol; 2018 Mar; 11(1):47. PubMed ID: 29580257
[TBL] [Abstract][Full Text] [Related]
8. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
9. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Jia Y; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
[TBL] [Abstract][Full Text] [Related]
10. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors.
Zhang L; Zhou C; Zhang S; Chen X; Liu J; Xu F; Liang W
Front Oncol; 2022; 12():939249. PubMed ID: 36003765
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors.
Li X; Yang Y; Huang Q; Deng Y; Guo F; Wang G; Liu M
Front Cell Dev Biol; 2021; 9():738373. PubMed ID: 34692696
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
14. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Gao L; Yang X; Yi C; Zhu H
Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
[No Abstract] [Full Text] [Related]
15. [Research Progress of Histone Deacetylase Inhibitor Combined with
Immune Checkpoint Inhibitor in the Treatment of Tumor].
Fang C; Wang Y; Li Y
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):204-211. PubMed ID: 33819971
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
17. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
19. The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.
Alimonti P; Gonzalez Castro LN
Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37092448
[TBL] [Abstract][Full Text] [Related]
20. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.
Kwon M; Jung H; Nam GH; Kim IS
J Control Release; 2021 Mar; 331():321-334. PubMed ID: 33434599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
